We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 18, 2021

Cardiorenal Outcomes and the Direct Medical Cost of T2D Patients Treated With SGLT2 Inhibitors and GLP-1RAs

Diabetes Research and Clinical Practice

 

Additional Info

Diabetes Research and Clinical Practice
Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study
Diabetes Res. Clin. Pract. 2021 Sep 27;[EPub Ahead of Print], E Ho Man Tang, C King Ho Wong, K Tsz Kwan Lau, Y Fei, B Man Yung Cheung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading